Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The purpose of this double-blind, randomized, controlled study is to assess immunogenicity and safety of 202-CoV at multiple dose levels, administered as 2 injections (i.m) at 28 days apart in adult subjects 18 years of age and above.
Epistemonikos ID: 3557f002f4f3432a349efa74624650fbbf6349ea
First added on: Aug 05, 2021